Fosfomycin-induced liver injury: A case report and literature review

Author:

Faragalla Kyrillos1,Cohen-Lyons Daniel2,Parvinnejad Nikoo3,Wang Hanlin L.4,Liu Jimin356

Affiliation:

1. Internal Medicine, University of Saskatchewan, Saskatoon, Ontario, Canada

2. Gastroenterology, Mackenzie Health, Richmond Hill, Ontario, Canada

3. Anatomic Pathology, Mackenzie Health, Richmond Hill, Ontario, Canada

4. Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, United States

5. Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

6. Correspondence: Jimin Liu, Department of Pathology and Laboratory Medicine, Mt Sinai Hospital, 600 University Ave., Toronto, ON, M5G 1X5, Telephone: +1 (905) 815-2688.

Abstract

Background: Fosfomycin is an antibiotic often used to treat urinary tract infections (UTIs) with only rare transient hepatotoxicity. We present a case of fosfomycin-induced liver injury and describe the histopathologic findings on biopsy. Methods: A 64-year-old female patient with no prior liver disease or risk factors was started on fosfomycin as prophylaxis for recurrent UTIs. Within a week of her first dose, she presented with fatigue, jaundice, and mixed liver enzyme elevation. Clinical workup for acute liver injury was unremarkable, and biopsy showed panacinar and portal necroinflammation with predominantly lymphocytic infiltrate and cholestasis, with no evidence of cirrhosis. This was thought to be likely related to fosfomycin exposure. Although liver enzymes trended down, bilirubin initially remained elevated. However, within 3 months the patient achieved clinical and biochemical recovery. Results: Only two other reports of fosfomycin-induced liver injury requiring biopsy were found. Both developed acute cholestatic hepatitis within days of exposure, and subsequent biopsy similarly showed lymphocytic necroinflammation. Although one patient initially developed acute liver failure, both recovered fully within a few months. Conclusion: Overall, these cases suggest potentially an idiosyncratic or immune-mediated liver toxicity of Fosfomycin, which is typically self-limited but may take months to fully resolve. Liver biopsy may be useful in confirming the diagnosis.

Publisher

University of Toronto Press Inc. (UTPress)

Reference16 articles.

1. Fosfomycin Tromethamine

2. THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)

3. Pharmacokinetic Profile of Fosfomycin Trometamol

4. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database

5. Food and Drug Administration. FDA AEs reporting system (FAERS) public dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Published September 2017. Accessed March 26, 2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3